Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Merck's Ending Cash Position for the quarter that ended in Jun. 2026 was CHF5,508 Mil.
Merck's quarterly Ending Cash Position
declined
from Dec. 2025 (CHF11,706 Mil) to Mar. 2026 (CHF4,250 Mil) but then
increased
from Mar. 2026 (CHF4,250 Mil) to Jun. 2026 (CHF5,508 Mil).
Merck's annual Ending Cash Position
increased
from Dec. 2023 (CHF5,975 Mil) to Dec. 2024 (CHF11,874 Mil) but then
declined
from Dec. 2024 (CHF11,874 Mil) to Dec. 2025 (CHF11,706 Mil).
The historical data trend for Merck's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
Merck's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of CHF5,508 Mil mean?
Merck (XSWX:MRK) has a Ending Cash Position of CHF5,508 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Merck and its competitors.
Is Merck's Ending Cash Position too high?
Merck's current Ending Cash Position is CHF5,508 Mil. Overall, Merck has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Merck's Ending Cash Position compare to AMGN and ABBV?
Merck's Ending Cash Position of CHF5,508 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Merck and its competitors. Merck's current Ending Cash Position is CHF5,508 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck stock overvalued right now?
Merck (XSWX:MRK) has a current Ending Cash Position of CHF5,508 Mil. The stock's GF Value™ is CHF95.97, compared to a current price of CHF122.12 — trading 27.2% above its estimated fair value. The current Ending Cash Position is CHF5,508 Mil. Merck's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Merck (XSWX:MRK), the current Ending Cash Position is CHF5,508 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Merck (XSWX:MRK) Overvalued in 2026?
Based on GuruFocus' analysis, Merck stock appears to be overvalued.
The current stock price of CHF122.12 is trading 27.2% above its estimated GF Value™ of CHF95.97.
Key valuation signals for XSWX:MRK:
Ending Cash Position: CHF5,508 Mil
GF Value™: CHF95.97 vs. price of CHF122.12 (27.2% above fair value)
No single metric tells the full story. See the XSWX:MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
71GF Score
Get the complete analysis for XSWX:MRK
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MRK has been successfully added to your 
